What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.29%
Annual Rate
CNY 0.02Paid unknown
Payout Ratio
29.5%Sustainable
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.13BCNY
1.14B · vs all stocks (USD)
Updated Nov 22, 2026
Trailing P/E
78.75x
vs Medical Devices peers
Updated Nov 22, 2026
Revenue (TTM)
2.06BCNY
308.56M · vs all stocks (USD)
Updated Nov 22, 2026
Profit Margin
4.06%
vs Medical Devices peers
Updated Nov 22, 2026
Beta
0.3220x
vs all stocks
Updated Nov 22, 2026
52-Week Change
-19.47%
vs all stocks
Updated Nov 22, 2026
Forward Annual Dividend Yield
0.29%
vs all stocks
Updated Nov 22, 2026
Market Capitalization
6.13BCNY
1.14B · vs all stocks (USD)
Updated Nov 22, 2026
Enterprise Value
5.89BCNY
1.06B · vs all stocks (USD)
Updated Nov 22, 2026
Trailing P/E
78.75x
vs Medical Devices peers
Updated Nov 22, 2026
Forward P/E
25.20x
vs Medical Devices peers
Updated Nov 22, 2026
Price to Sales (TTM)
2.97x
vs Medical Devices peers
Updated Nov 22, 2026
Price to Book (MRQ)
2.52x
vs Medical Devices peers
Updated Nov 22, 2026
Enterprise to Revenue
2.86x
vs Medical Devices peers
Updated Nov 22, 2026
Enterprise to EBITDA
19.65x
vs Medical Devices peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 23.03×.Updated Nov 22, 2026
Gross Margin
32.05%
vs Medical Devices peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 27.65%.Updated Nov 22, 2026
Profit Margin
4.06%
vs Medical Devices peers
Updated Nov 22, 2026
Operating Margin
11.98%
vs Medical Devices peers
Updated Nov 22, 2026
Return on Assets (TTM)
3.74%
vs Medical Devices peers
Updated Nov 22, 2026
Return on Equity (TTM)
4.54%
vs Medical Devices peers
Updated Nov 22, 2026
Revenue (TTM)
2.06BCNY
308.56M · vs all stocks (USD)
Updated Nov 22, 2026
Revenue per Share (TTM)
2.08CNYUpdated Nov 22, 2026
Quarterly Revenue Growth
0.40%
vs Medical Devices peers
Updated Nov 22, 2026
Gross Profit (TTM)
569.88MCNY
85.21M · vs all stocks (USD)
Updated Nov 22, 2026
EBITDA (TTM)
255.98MCNY
38.36M · vs all stocks (USD)
Updated Nov 22, 2026
Net Income (TTM)
83.70MCNY
11.11M · vs all stocks (USD)
Updated Nov 22, 2026
Quarterly Earnings Growth (YoY)
38.30%
vs Medical Devices peers
Updated Nov 22, 2026
Operating Cash Flow (TTM)
494.97MCNY
71.62M · vs all stocks (USD)
Updated Nov 22, 2026
Levered Free Cash Flow (TTM)
-23.53MCNY
34.79M · vs all stocks (USD)
Updated Nov 22, 2026
Forward Annual Dividend Rate
0.0200CNYUpdated Nov 22, 2026
Forward Annual Dividend Yield
0.29%
vs all stocks
Updated Nov 22, 2026
Trailing Annual Dividend Rate
0.0190CNYUpdated Nov 22, 2026
Trailing Annual Dividend Yield
0.28%
vs all stocks
Updated Nov 22, 2026
Payout Ratio
29.51%
vs Medical Devices peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 23.75%.Updated Nov 22, 2026
Minority Interest (Equity)
104.03MCNYFY2025 · Dec 31, 2025
Revenue
1.89BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
1.37BCNYFY2025 · Dec 31, 2025
Gross Profit
510.93MCNYFY2025 · Dec 31, 2025
Operating Income
231.36MCNY
34.67M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
151.64MCNYFY2025 · Dec 31, 2025
Income Tax Expense
64.29MCNYFY2025 · Dec 31, 2025
Net Income
87.35MCNYFY2025 · Dec 31, 2025
EBIT
171.30MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
343.56MCNYFY2025 · Dec 31, 2025
Research & Development
49.19MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
59.09MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
8.92MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
11.33MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
19.66MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.0692CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.0692CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
990.03MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
990.03MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
87.35MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-18.81MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
133.01MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-93.52MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
1.06BCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
87.35MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
32.44MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
2.32MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
10.91MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-226.53MCNYFY2025 · Dec 31, 2025
Net Acquisitions
-368.78MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-1.82BCNYFY2025 · Dec 31, 2025
Sale of Investments
1.75BCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-672.57MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
368.89MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-123.03MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-10.48MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-68.08MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
167.31MCNYFY2025 · Dec 31, 2025
Shares Outstanding
972.93MSharesUpdated Nov 22, 2026
Float Shares
469.35MSharesUpdated Nov 22, 2026
% Held by Insiders
57.78%
vs all stocks
Updated Nov 22, 2026
% Held by Institutions
1.78%
vs all stocks
Updated Nov 22, 2026
Total Cash (MRQ)
1.07BCNY
204.11M · vs all stocks (USD)
Updated Nov 22, 2026
Total Cash per Share (MRQ)
1.11CNYUpdated Nov 22, 2026
Total Debt (MRQ)
805.20MCNY
124.72M · vs all stocks (USD)
Updated Nov 22, 2026
Total Debt to Equity (MRQ)
0.3234x
vs Medical Devices peers
Updated Nov 22, 2026
Current Ratio (MRQ)
2.48x
vs Medical Devices peers
Updated Nov 22, 2026
Book Value per Share (MRQ)
2.50CNYUpdated Nov 22, 2026
Total Assets
4.19BCNY
628.34M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.83BCNYFY2025 · Dec 31, 2025
Total Liabilities
1.58BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
2.36BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
692.89MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
883.34MCNYFY2025 · Dec 31, 2025
Cash
1.07BCNYFY2025 · Dec 31, 2025
Cash Equivalents
195.94KCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
1.07BCNYFY2025 · Dec 31, 2025
Other Short-term Investments
199.00MCNYFY2025 · Dec 31, 2025
Accounts Receivable
297.97MCNYFY2025 · Dec 31, 2025
Inventory
87.16MCNYFY2025 · Dec 31, 2025
Accounts Payable
271.43MCNYFY2025 · Dec 31, 2025
Short-term Debt
163.57MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
6.99MCNYFY2025 · Dec 31, 2025
Long-term Debt
607.35MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
9.46MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
749.45MCNYFY2025 · Dec 31, 2025
Retained Earnings
70.29MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
2.62BCNY
392.11M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
38.24MCNYFY2025 · Dec 31, 2025
52-Week Low
6.30CNYUpdated Nov 22, 2026
52-Week High
11.06CNYUpdated Nov 22, 2026
52-Week Change
-19.47%
vs all stocks
Updated Nov 22, 2026
Beta
0.3220x
vs all stocks
Updated Nov 22, 2026
50-Day MA
7.51CNYUpdated Nov 22, 2026
200-Day MA
8.02CNYUpdated Nov 22, 2026
Avg 10-Day Volume
5.38MSharesUpdated Nov 22, 2026
Avg 30-Day Volume
6.27MSharesUpdated Nov 22, 2026
Diluted EPS (TTM)
0.0800CNYUpdated Nov 22, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Near 52W Low With Profitability And FCF
Within 1% of its 52-week low, profitable three years, and capex takes less of its cash flow than at most of its peers.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.